Welcome to our dedicated page for Integrated Biopharma SEC filings (Ticker: INBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Integrated BioPharma, Inc. filings document formal disclosures for a Delaware operating company whose public reports are tied to vitamins, nutritional supplements, herbal products and contract manufacturing. Recent Form 8-K filings furnish quarterly and fiscal-year results under Item 2.02, including press-release exhibits covering revenue, operating results and per-share data.
The filing record also includes material-event reports on credit-line arrangements and related-party lease matters involving the wholly owned subsidiary Manhattan Drug Company, as well as definitive proxy materials and annual meeting voting results covering director elections, executive-compensation votes, stockholder voting matters and governance procedures. Cover-page disclosures identify no securities registered on a national exchange under Section 12(b).
Integrated BioPharma, Inc. reported weaker results for the quarter and six months ended December 31, 2025, as lower sales and thinner margins led to losses. Quarterly net sales fell to $11.3 million from $12.6 million, and the company swung to a net loss of $0.8 million versus prior-year profit.
For the six-month period, net sales declined to $24.0 million from $26.2 million, while net income of $0.4 million a year earlier turned into a net loss of about $0.6 million. Gross margin compressed significantly as cost of sales rose as a percentage of revenue, reflecting lower volumes to cover fixed manufacturing costs and pressure from inflation and labor markets.
The business remains highly concentrated, with two contract manufacturing customers accounting for roughly 89% of six‑month net sales. Despite the loss, liquidity improved: cash increased to $5.3 million, operating cash flow reached $1.9 million, and the company had no borrowings under its up to $4.5 million credit facilities, supporting working capital of about $14.3 million.
Integrated BioPharma Inc. reported an equity award to a senior insider. On 12/09/2025, Co-Chief Executive Officer, director and 10% owner Christina Kay received a stock option covering 140,000 shares of common stock at an exercise price of $0.35 per share. Following this grant, she beneficially owns 140,000 derivative securities in the form of this option. The option vests in three equal annual installments, with the first tranche vesting on December 9, 2026, aligning her compensation with longer-term shareholder performance.
Integrated BioPharma Inc. reported a new equity award to its Co-Chief Executive Officer and director, Riva Sheppard. On 12/09/2025, Sheppard received a stock option to purchase 140,000 shares of common stock at an exercise price of $0.35 per share. The option has an expiration date of December 9, 2035 and vests in three equal annual installments, with the first tranche vesting on December 9, 2026. Following this grant, Sheppard holds 140,000 derivative securities directly.
Integrated BioPharma Inc. reported a new stock option grant to its Chief Financial Officer, Dina L. Masi. On 12/09/2025, she received an option to purchase 140,000 shares of the company’s common stock at an exercise price of $0.31 per share. The option has an expiration date of 12/09/2035, giving a long-term window to exercise.
The option vests in three equal annual installments, with the first installment becoming exercisable on December 9, 2026. This means the grant is designed as a multi-year incentive, aligning the CFO’s potential equity gains with the company’s performance over time.
Integrated BioPharma, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 1, 2025. Of 31,059,610 common shares entitled to vote as of October 17, 2025, holders of 22,651,488 shares were present in person or by proxy, establishing a quorum.
Stockholders elected Class III director Eric Friedman to serve until the 2028 Annual Meeting, with 20,662,516 votes for, 183,398 withheld and 1,805,574 broker non-votes. They approved, on a non-binding basis, holding the advisory vote on executive compensation every three years, with 20,395,034 votes supporting a three-year frequency.
Stockholders also gave non-binding approval to the executive compensation for the named executive officers, with 20,788,236 votes for, 56,978 against and 700 abstentions, plus 1,805,574 broker non-votes. In addition, they ratified the appointment of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026, with 22,536,930 votes for, 113,420 against and 1,138 abstentions.
Integrated Biopharma, Inc. furnished an earnings press release for the quarter ended September 30, 2025. The release is attached as Exhibit 99.1 and provides the company’s quarterly financial results.
The information was furnished under Item 2.02 and, along with Exhibit 99.1, is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists the exhibit index and confirms the materials are provided via Inline XBRL.
Integrated BioPharma (INBP) reported lower quarterly results for the three months ended September 30, 2025. Sales, net were $12,689 (down 6.8% year over year), and gross profit was $1,019 versus $1,371 a year ago as cost of sales rose to 92.0% of sales. Operating income fell to $163 from $490, and net income was $123 compared with $259 in the prior-year quarter.
Customer concentration remained high: two contract manufacturing customers represented 87% of consolidated net sales, with Life Extension at 71% and Herbalife at 20% of segment sales. Operating cash flow improved to $1,301 from $657, lifting cash to $4,732. Working capital was approximately $14,860.
The company had no borrowings and access to a revolving credit facility and a convertible equipment line totaling about $4,500. Management cited inflation and tight labor markets as margin headwinds while keeping selling and administrative expenses near flat.
Integrated BioPharma, Inc. (INBP) filed its definitive proxy and set the 2025 Annual Meeting for December 1, 2025 at 9:00 a.m. local time at its Hillside, NJ offices. Stockholders will vote on: (1) electing Class III director nominee Eric Friedman for a three-year term; (2) a non-binding advisory vote on executive compensation (say‑on‑pay); (3) a non-binding advisory vote on the frequency of say‑on‑pay; and (4) ratifying CBIZ CPAs P.C. as independent auditor for the fiscal year ending June 30, 2026.
The Board unanimously recommends FOR the director nominee, FOR say‑on‑pay, THREE YEARS for say‑on‑pay frequency, and FOR auditor ratification. Holders of record as of October 17, 2025 may vote; 31,059,610 shares of common stock were outstanding on the record date. Proxy materials are available at materials.proxyvote.com/45811V.
Integrated Biopharma, Inc. filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The company clarifies the furnished information is not "filed" for Section 18 liability purposes and has attached the exhibit in Item 9.01.
Integrated Biopharma, Inc. filed a Form 8-K reporting that on September 23, 2025 it issued a press release announcing its financial results for the quarter and fiscal year ended June 30, 2025. The filing states the press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The company clarifies the furnished information is not "filed" for Section 18 liability purposes and has attached the exhibit in Item 9.01.
Integrated BioPharma, Inc. (INBP) reports consolidated fiscal-year information and disclosures for the year ended June 30, 2025. The company states it has a cybersecurity program based on recognized standards and is not aware of any cybersecurity incidents that have materially affected its business. The balance sheet notes 50,000,000 shares authorized and roughly 31.1 million shares outstanding reported in the filing. The company recorded a $20 allowance for credit losses at June 30, 2025 (versus $1 at June 30, 2024). Two customers accounted for approximately 84% of consolidated net sales in 2025 and represented about 76% of accounts receivable at June 30, 2025. The filing discloses federal and state NOLs with limited realizability and a valuation allowance changes: a $830 reserve recorded against federal NOL-related deferred tax assets and a $347 release of the state NOL valuation reserve due to tax law change. Lease amendments and stock option plan details (plans with 4,659,652 shares remaining; recent option grants and exercise prices) are included, and a finance lease obligation of $485 due to a related party is disclosed.
Integrated BioPharma, Inc. (INBP) reports consolidated fiscal-year information and disclosures for the year ended June 30, 2025. The company states it has a cybersecurity program based on recognized standards and is not aware of any cybersecurity incidents that have materially affected its business. The balance sheet notes 50,000,000 shares authorized and roughly 31.1 million shares outstanding reported in the filing. The company recorded a $20 allowance for credit losses at June 30, 2025 (versus $1 at June 30, 2024). Two customers accounted for approximately 84% of consolidated net sales in 2025 and represented about 76% of accounts receivable at June 30, 2025. The filing discloses federal and state NOLs with limited realizability and a valuation allowance changes: a $830 reserve recorded against federal NOL-related deferred tax assets and a $347 release of the state NOL valuation reserve due to tax law change. Lease amendments and stock option plan details (plans with 4,659,652 shares remaining; recent option grants and exercise prices) are included, and a finance lease obligation of $485 due to a related party is disclosed.